# Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/characterizing-collecting-and-reporting-immune-mediated-adverse-reactions-in-cancer-immunotherapeutic-clinical-trials-draft-guidance-for-industry-availability/f687702e-a09a-4529-b573-6d8a028c8779

> FDA guidance document: Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability. Issue date: October 17, 2022. Get complete insights and analysis.

---

## Details

- Title: Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2022-10-17
- Last Changed: 2022-10-17
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-1744">FDA-2022-D-1744</a>

## Related Documents

- [Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-approaches-to-obtain-data-on-populations-underrepresented-in-clinical-trials-for-drugs-and-biological-products/46edf900-58f2-4f79-bf45-4baa56d25006)
- [Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics/adf9cb72-5955-4d5f-8f26-4e226281ace9)
- [Risk Management Plans to Mitigate the Potential for Drug Shortages](https://www.globalkeysolutions.net/guidances/guidance-document/risk-management-plans-to-mitigate-the-potential-for-drug-shortages/bd27fc63-0c90-4718-abd5-2b5af99e540e)